<DOC>
	<DOC>NCT00584532</DOC>
	<brief_summary>Genistein Combined Polysaccharide (GCP) may play a role as a secondary chemopreventive agent in the treatment of localized prostate cancer.</brief_summary>
	<brief_title>Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<criteria>Participants must be male and have a pathological diagnosis of prostate cancer Pathological diagnosis of prostate cancer must be confirmed and on file with CRA prior to study entry. No treatment (surgery, radiation, or hormones) prior to study entry. PSA between 2.0 and 10.0 ng/ml. If PSA is &gt;10.0, patient must have been on Active Surveillance for 12 months prior to study initiation. No known allergy to soy or soy products. The patient is not currently taking more than 2 grams of genistein a day in nutritional or diet enhancing supplements (OTC supplements). Participant has not been on any previous GCP clinical trial. Normal Chemistry values prior to study entry. No pathological documentation of prostate cancer. Prior treatment for prostate cancer. PSA &gt;10.0 ng/ml but not on Active Surveillance for 12 months. Allergy to soy or soy products. Abnormal chemistry values.</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Localized</keyword>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
</DOC>